For example, in one report of 50 patients with biochemical recurrence and PSA levels of 0.2 to 2.0 ng/dL, PSMA PET has significantly greater detection rates over [18F]-fluciclovine PET-CT for overall disease (56% vs. 26%), as well as pelvic nodal (30% vs. 8%) and extra-pelvic (16% vs. 0%) sites of prostate cancer [92]. This evidence concerns the gene FOLH1 and Familial prostate cancer.